References

References

  1. NeuroStar Prescribing Information.
  2. World Health Organization. Depression fact sheet No.369. http://www.who.int/mediacentre/factsheets/fs369/en/index.html. Accessed February 27, 2013.
  3. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed March 12, 2013.
  4. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).
  5. Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 69(2):222-232.
  6. Data on file. Neuronetics, Inc.
  7. O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.
  8. George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.
  9. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice. Depress Anxiety, 29(7):587-596.
  10. Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.
  11. McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.
  12. Janicak PG, et al. (2010). Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 3(4):187-199.
  13. Demitrack MA, Thase ME. (2009). Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull, 42(2):5-38.
  14. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526
  15. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. www.who.int/whr/2001/en/whr01_en.pdf. Accessed March 12, 2013.
  16. Kessler, RC et al. (2003). Epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.
  17. World Health Organization. The ICD-10 classifications of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. www.who.int/classifications/icd/en/bluebook.pdf. Accessed March 12, 2013.
  18. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  19. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.
  20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.
  21. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depress Anxiety, 29 (10):883-890.

1. NeuroStar Prescribing Information.

2. World Health Organization. Depression fact sheet No.369. LINK. Accessed February 27, 2013.

3. World Health Organization. The global burden of disease: 2004 update. LINK. Accessed March 12, 2013.

4. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).

5. Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 69(2):222-232.

6. Data on file. Neuronetics, Inc.

7. O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.

8. George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.

9. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice. Depress Anxiety, 29(7):587-596.

10. Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.

11. McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.

12. Janicak PG, et al. (2010). Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 3(4):187-199.

13. Demitrack MA, Thase ME. (2009). Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull, 42(2):5-38.

14. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526

15. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. LINK. Accessed March 12, 2013.

16. Kessler, RC et al. (2003). Epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.

17. World Health Organization. The ICD-10 classifications of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. LINK. Accessed March 12, 2013.

18. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.

19. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.

20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.

21. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depress Anxiety, 29 (10):883-890.

The information contained in this website is only intended for international markets, excluding the United States.

Indication
NeuroStar TMS Therapy is indicated for the treatment of adult patients with Major Depressive Disorder (MDD) who have failed to receive satisfactory improvement from antidepressant medications.

NeuroStar TMS Therapy is only available by prescription. A doctor can help decide if NeuroStar TMS Therapy is right for you.

Important Safety Information
NeuroStar TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head.

NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant medication treatment.

The most common side effect is pain or discomfort at or near the treatment site. There is a rare risk of seizure associated with the use of NeuroStar TMS (<0.1% per patient). You should talk with a NeuroStar physician to determine if TMS Therapy may be right for you.

Copyright @ 2024 Neuronetics. All Rights Reserved.

X-twitter Youtube